 Suchitra Rao
Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 38 | 2026 | 635 | 10.470 |
Why?
| | Influenza Vaccines | 20 | 2025 | 553 | 4.710 |
Why?
| | Vaccination | 22 | 2025 | 1479 | 2.680 |
Why?
| | Respiratory Syncytial Virus Infections | 5 | 2025 | 134 | 2.480 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 389 | 2.360 |
Why?
| | Hospitalization | 34 | 2026 | 2293 | 2.240 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2024 | 81 | 2.240 |
Why?
| | Systemic Inflammatory Response Syndrome | 6 | 2024 | 95 | 1.760 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2025 | 153 | 1.560 |
Why?
| | Child | 64 | 2026 | 22562 | 1.540 |
Why?
| | Emergency Service, Hospital | 19 | 2025 | 2251 | 1.510 |
Why?
| | Child, Preschool | 46 | 2026 | 11634 | 1.450 |
Why?
| | Infant | 32 | 2026 | 9908 | 1.300 |
Why?
| | Antiviral Agents | 9 | 2026 | 758 | 1.300 |
Why?
| | Influenza A Virus, H3N2 Subtype | 7 | 2026 | 49 | 1.240 |
Why?
| | Coinfection | 2 | 2022 | 133 | 1.000 |
Why?
| | Absenteeism | 2 | 2024 | 52 | 0.990 |
Why?
| | Retrospective Studies | 31 | 2026 | 16626 | 0.990 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 85 | 0.960 |
Why?
| | Oseltamivir | 3 | 2025 | 14 | 0.940 |
Why?
| | Humans | 109 | 2026 | 142526 | 0.940 |
Why?
| | Ambulatory Care | 10 | 2026 | 598 | 0.930 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 30 | 0.910 |
Why?
| | Croup | 1 | 2024 | 19 | 0.870 |
Why?
| | Polyomavirus | 3 | 2016 | 12 | 0.870 |
Why?
| | Immunocompromised Host | 3 | 2021 | 206 | 0.860 |
Why?
| | Bronchiolitis | 1 | 2024 | 84 | 0.810 |
Why?
| | Adolescent | 49 | 2026 | 22326 | 0.800 |
Why?
| | Colorado | 12 | 2023 | 4638 | 0.800 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.780 |
Why?
| | Immunization Programs | 1 | 2025 | 223 | 0.760 |
Why?
| | Metapneumovirus | 1 | 2022 | 15 | 0.750 |
Why?
| | Seizures | 3 | 2024 | 452 | 0.740 |
Why?
| | Male | 58 | 2026 | 70910 | 0.710 |
Why?
| | Seasons | 11 | 2026 | 554 | 0.700 |
Why?
| | Myocarditis | 1 | 2022 | 99 | 0.700 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 277 | 0.680 |
Why?
| | Female | 58 | 2026 | 76624 | 0.660 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 103 | 0.650 |
Why?
| | Endpoint Determination | 1 | 2020 | 78 | 0.640 |
Why?
| | Viruses | 1 | 2022 | 163 | 0.640 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 467 | 0.620 |
Why?
| | Birth Order | 1 | 2019 | 13 | 0.590 |
Why?
| | Advisory Committees | 1 | 2020 | 215 | 0.590 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 180 | 0.590 |
Why?
| | Streptococcal Infections | 1 | 2021 | 158 | 0.580 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.580 |
Why?
| | United States | 35 | 2026 | 15447 | 0.560 |
Why?
| | Encephalitis | 2 | 2017 | 137 | 0.560 |
Why?
| | Sinusitis | 1 | 2021 | 239 | 0.560 |
Why?
| | Nervous System Diseases | 1 | 2020 | 280 | 0.510 |
Why?
| | Viral Load | 4 | 2024 | 511 | 0.510 |
Why?
| | Electronic Health Records | 6 | 2025 | 1144 | 0.500 |
Why?
| | Medical Audit | 1 | 2016 | 77 | 0.490 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 369 | 0.480 |
Why?
| | Leukoencephalitis, Acute Hemorrhagic | 2 | 2025 | 5 | 0.470 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1881 | 0.470 |
Why?
| | Cohort Studies | 12 | 2025 | 5858 | 0.460 |
Why?
| | Family Characteristics | 3 | 2025 | 192 | 0.450 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 87 | 0.450 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 44 | 0.450 |
Why?
| | Virus Shedding | 2 | 2026 | 48 | 0.440 |
Why?
| | Young Adult | 22 | 2026 | 13878 | 0.440 |
Why?
| | Acyclovir | 1 | 2015 | 96 | 0.430 |
Why?
| | Infant, Newborn | 12 | 2026 | 6324 | 0.430 |
Why?
| | Attitude to Health | 1 | 2017 | 451 | 0.420 |
Why?
| | Case-Control Studies | 9 | 2023 | 3604 | 0.420 |
Why?
| | Enterovirus Infections | 1 | 2016 | 174 | 0.420 |
Why?
| | Ritonavir | 2 | 2024 | 72 | 0.410 |
Why?
| | Hospitals, Pediatric | 2 | 2025 | 551 | 0.400 |
Why?
| | Adult | 38 | 2026 | 39715 | 0.400 |
Why?
| | Health Promotion | 1 | 2019 | 755 | 0.400 |
Why?
| | Pandemics | 4 | 2025 | 1661 | 0.390 |
Why?
| | Infection Control | 1 | 2014 | 172 | 0.380 |
Why?
| | Mothers | 1 | 2019 | 781 | 0.370 |
Why?
| | Body Mass Index | 4 | 2026 | 2406 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1773 | 0.360 |
Why?
| | Outpatients | 3 | 2025 | 425 | 0.360 |
Why?
| | Virus Diseases | 1 | 2014 | 218 | 0.360 |
Why?
| | Brain Diseases | 2 | 2025 | 151 | 0.360 |
Why?
| | Cross Infection | 1 | 2014 | 260 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1353 | 0.350 |
Why?
| | Anticonvulsants | 2 | 2024 | 227 | 0.350 |
Why?
| | Health Personnel | 1 | 2017 | 731 | 0.340 |
Why?
| | Hematologic Diseases | 1 | 2011 | 66 | 0.340 |
Why?
| | Cost of Illness | 3 | 2026 | 316 | 0.330 |
Why?
| | Immunization, Secondary | 4 | 2022 | 92 | 0.310 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.300 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.300 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.290 |
Why?
| | Parents | 1 | 2017 | 1450 | 0.290 |
Why?
| | Program Evaluation | 2 | 2025 | 928 | 0.290 |
Why?
| | Peritonitis | 1 | 2009 | 83 | 0.280 |
Why?
| | Pleural Effusion | 1 | 2009 | 60 | 0.280 |
Why?
| | Influenza A virus | 2 | 2026 | 112 | 0.280 |
Why?
| | Electroencephalography | 2 | 2024 | 531 | 0.270 |
Why?
| | Risk Factors | 9 | 2025 | 10593 | 0.260 |
Why?
| | Prospective Studies | 7 | 2026 | 7862 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 829 | 0.260 |
Why?
| | Severity of Illness Index | 5 | 2025 | 2927 | 0.250 |
Why?
| | Motivation | 2 | 2022 | 606 | 0.250 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.240 |
Why?
| | Strongylida Infections | 2 | 2018 | 7 | 0.240 |
Why?
| | Middle Aged | 23 | 2026 | 35049 | 0.240 |
Why?
| | Aged | 18 | 2026 | 25117 | 0.230 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 139 | 0.220 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 38 | 0.210 |
Why?
| | Population Surveillance | 2 | 2025 | 485 | 0.210 |
Why?
| | Dyslipidemias | 1 | 2026 | 178 | 0.210 |
Why?
| | Disease Progression | 4 | 2024 | 2831 | 0.210 |
Why?
| | Pediatrics | 2 | 2025 | 1110 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 126 | 0.200 |
Why?
| | Antigens, Viral | 1 | 2024 | 179 | 0.200 |
Why?
| | Vaccines, Combined | 4 | 2023 | 49 | 0.200 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 345 | 0.200 |
Why?
| | RNA, Messenger | 7 | 2024 | 2828 | 0.200 |
Why?
| | Physicians | 2 | 2023 | 937 | 0.190 |
Why?
| | Child, Hospitalized | 1 | 2023 | 54 | 0.190 |
Why?
| | Vital Signs | 1 | 2022 | 49 | 0.190 |
Why?
| | Inpatients | 2 | 2017 | 517 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 343 | 0.180 |
Why?
| | Length of Stay | 2 | 2025 | 1273 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Cough | 1 | 2022 | 133 | 0.180 |
Why?
| | Patient Readmission | 2 | 2024 | 703 | 0.180 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.170 |
Why?
| | Aged, 80 and over | 8 | 2026 | 8020 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2025 | 565 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 879 | 0.160 |
Why?
| | Drug Utilization | 2 | 2024 | 166 | 0.160 |
Why?
| | Public Health | 1 | 2025 | 561 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 31 | 0.160 |
Why?
| | Algorithms | 2 | 2025 | 1791 | 0.160 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 45 | 0.150 |
Why?
| | Immunization Schedule | 2 | 2021 | 202 | 0.150 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.150 |
Why?
| | Antibodies, Viral | 2 | 2023 | 664 | 0.150 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 128 | 0.140 |
Why?
| | Information Dissemination | 1 | 2020 | 210 | 0.140 |
Why?
| | Incidence | 2 | 2025 | 2826 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 148 | 0.140 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 108 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 416 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 391 | 0.140 |
Why?
| | Reminder Systems | 1 | 2019 | 175 | 0.140 |
Why?
| | Oxygen | 1 | 2023 | 991 | 0.140 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 243 | 0.140 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 239 | 0.130 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 73 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2020 | 165 | 0.130 |
Why?
| | Pneumonia | 2 | 2016 | 643 | 0.130 |
Why?
| | Nurses | 1 | 2019 | 186 | 0.130 |
Why?
| | Disease Outbreaks | 2 | 2020 | 428 | 0.130 |
Why?
| | Adiposity | 1 | 2022 | 528 | 0.130 |
Why?
| | Philippines | 1 | 2016 | 52 | 0.120 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 68 | 0.120 |
Why?
| | Fatigue | 1 | 2018 | 346 | 0.120 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.120 |
Why?
| | Nasal Cavity | 1 | 2016 | 62 | 0.120 |
Why?
| | Patient Discharge | 2 | 2019 | 920 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 485 | 0.120 |
Why?
| | Neoplasms | 1 | 2011 | 2761 | 0.120 |
Why?
| | Influenza B virus | 2 | 2025 | 45 | 0.120 |
Why?
| | Zoonoses | 1 | 2015 | 36 | 0.120 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 39 | 0.120 |
Why?
| | Critical Care | 1 | 2021 | 673 | 0.110 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 115 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 21 | 0.110 |
Why?
| | Hospital Mortality | 3 | 2025 | 952 | 0.110 |
Why?
| | Dog Diseases | 1 | 2015 | 69 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1144 | 0.110 |
Why?
| | Time Factors | 4 | 2025 | 7006 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 673 | 0.110 |
Why?
| | Rural Population | 1 | 2019 | 611 | 0.110 |
Why?
| | Hospitals | 3 | 2024 | 690 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 421 | 0.100 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 149 | 0.100 |
Why?
| | Bayes Theorem | 2 | 2026 | 424 | 0.100 |
Why?
| | Vaccination Coverage | 2 | 2025 | 104 | 0.100 |
Why?
| | Pregnancy | 3 | 2022 | 7113 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 1015 | 0.090 |
Why?
| | Survival Rate | 1 | 2017 | 1995 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1255 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 81 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2102 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 957 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 106 | 0.080 |
Why?
| | Eosinophilia | 1 | 2013 | 225 | 0.080 |
Why?
| | Critical Illness | 1 | 2016 | 857 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2227 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1642 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5994 | 0.080 |
Why?
| | Administration, Oral | 2 | 2026 | 835 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | DNA, Viral | 1 | 2011 | 364 | 0.070 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 10 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5700 | 0.070 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 15 | 0.070 |
Why?
| | Metronidazole | 1 | 2009 | 19 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1244 | 0.070 |
Why?
| | Drainage | 1 | 2009 | 177 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2817 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2025 | 874 | 0.070 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.070 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 13 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 35 | 0.070 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 36 | 0.070 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 31 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2023 | 11298 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3819 | 0.060 |
Why?
| | Animals | 6 | 2018 | 37697 | 0.060 |
Why?
| | Viral Proteins | 1 | 2009 | 370 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2980 | 0.060 |
Why?
| | Plasmapheresis | 1 | 2025 | 24 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 26 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 675 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 6 | 0.060 |
Why?
| | Safety | 1 | 2007 | 356 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2875 | 0.050 |
Why?
| | Lopinavir | 1 | 2024 | 28 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1501 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3776 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 134 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2025 | 245 | 0.050 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | Genotype | 1 | 2009 | 1866 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2025 | 304 | 0.050 |
Why?
| | Pediatricians | 1 | 2025 | 131 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 30 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 369 | 0.050 |
Why?
| | Acetamides | 1 | 2023 | 37 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 52 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 164 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 127 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 48 | 0.050 |
Why?
| | Diabetic Ketoacidosis | 1 | 2023 | 210 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 3027 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1977 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2023 | 473 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2771 | 0.040 |
Why?
| | Research Design | 1 | 2024 | 1113 | 0.030 |
Why?
| | Machine Learning | 1 | 2023 | 567 | 0.030 |
Why?
| | Pediatric Obesity | 1 | 2024 | 617 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1552 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1319 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 172 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5270 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1458 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 94 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1678 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 357 | 0.030 |
Why?
| | Cats | 1 | 2015 | 226 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3562 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3184 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 426 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3316 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2013 | 26 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1051 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 133 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 170 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 396 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 15 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 853 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|